RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy.
Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
孤儿核受体4A1(NR4A1,Nur77)在肿瘤微环境(TME)中调控免疫细胞代谢和功能方面发挥关键作用,从而影响癌症进展,并作为癌症免疫治疗的潜在治疗靶点。目前该领域缺乏一篇全面综述,讨论NR4A1在免疫细胞中的多方面作用以及如何利用这些知识进行治疗开发。本综述探讨了NR4A1在肿瘤相关免疫细胞中的多种功能,包括T细胞、单核细胞、NK 细胞、B细胞、树突状细胞、巨噬细胞和中性粒细胞。NR4A1通过影响细胞因子产生、细胞分化和免疫细胞耗竭来参与免疫调节。
我们重点阐述了TME中免疫细胞内的NR4A1可能因癌症和免疫细胞背景的不同而成为阳性预后因素(例如结肠癌中的巨噬细胞)或阴性预后因素(例如黑色素瘤中的T细胞)。
此外,本综述还重点介绍了靶向NR4A1的潜在治疗策略,包括抑制、激活或降解NR4A1以恢复免疫细胞功能并增强抗肿瘤免疫。此类疗法可能通过改变免疫细胞行为、阻断内在肿瘤生长通路或通过这两种机制来改善患者预后。
然而,NR4A1靶向疗法的开发将依赖于进一步研究,以更好地理解NR4A1的谱系特异性作用以及不同癌症类型和免疫细胞中的潜在机制。
Orphan nuclear receptor 4A1 (NR4A1, Nur77) plays a crucial role in regulating immune cell metabolism and function within the tumor microenvironment (TME), thus influencing cancer progression and serving as a potential therapeutic target for cancer immunotherapy. A comprehensive review discussing the multifaceted roles of NR4A1 in immune cells and the exploitation of that knowledge for therapeutic development is lacking in the field.
This review explores diverse functions of NR4A1 in tumor-associated immune cells, including T cells, monocytes, natural killer cells, B cells, dendritic cells, macrophages, and neutrophils. NR4A1 contributes to immune regulation by impacting cytokine production, cell differentiation, and immune cell exhaustion.
We highlight how NR4A1 in immune cells within the TME may be either a positive (e. g. , macrophages in colon cancer) or negative prognostic factor (e. g. , T cells in melanoma), depending on the cancer and immune cell context.
Additionally, this review also highlights potential therapeutic strategies targeting NR4A1, leading to its inhibition, activation, or degradation to restore immune cell function and enhance anti-tumor immunity. Such therapies could potentially improve patient outcomes by altering immune cell behaviors, blocking intrinsic tumor growth pathways, or via both mechanisms.
However, the development of NR4A1-targeted therapies will be dependent on further research to better understand lineage-specific roles of NR4A1 and the underlying mechanisms across different cancer types and immune cells.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。